Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

2.

NPM1-Mutated AML: Not All Treatments Are Equal

3.

mRNA-based COVID vaccines generate improved responses to immunotherapy

4.

Some triple negative breast cancers might be avoided by longer breastfeeding

5.

Telemedicine Not Reaching Rural Psychiatric Patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot